[Cannabinoids in medicine].

“Cannabinoids have been known for many centuries because of their various effects in healthcare. They are primarily effective in reducing nausea, vomiting, pain, anorexia, spasticity and depression. Some other effects are known, all seem to be mediated by cannabinoid receptors in the central nervous system. In the past years, medical use has been proven in several studies. Today, the therapeutical use of cannabinoids in medicine is increasing, and access was made easier. Especially in pain-management and palliative care, they seem to be a valuable therapeutic option.”

http://www.ncbi.nlm.nih.gov/pubmed/19165445

Therapeutic potential of cannabis in pain medicine†

BJA

“Cannabis has been of medicinal and social significance for millennia.

It is obtained from Cannabis sativa and the plant’s name reflects its ancient use—cannabis may represent a compound of Sanskrit and Hebrew words meaning ‘fragrant cane’, while sativa is Latin for cultivated.

Cannabis is also known as hemp.

Marijuana describes the dried cannabis flowers and leaves which are smoked, while hashish refers to blocks of cannabis resin which can be eaten.

Advances in cannabis research have paralleled developments in opioid pharmacology whereby a psychoactive plant extract has elucidated novel endogenous signalling systems with therapeutic significance.

Cannabinoids (CBs) are chemical compounds derived from cannabis.

This review discusses the basic science and clinical aspects of CB pharmacology with a focus on pain medicine.

Advances in cannabis research have ensured a future for these analgesic molecules which have been used since antiquity.”

http://bja.oxfordjournals.org/content/101/1/59.long

http://www.thctotalhealthcare.com/category/pain-2/

Cannabis in medicine: a national educational needs assessment among Canadian physicians.

“There is increasing global awareness and interest in the use of cannabis for therapeutic purposes (CTP).

It is clear that health care professionals need to be involved in these decisions, but often lack the education needed to engage in informed discussions with patients. This study was conducted to determine the educational needs of Canadian physicians regarding CTP…

 We have identified several key educational needs among Canadian physicians regarding CTP. These data can be used to develop resources and educational programs to support clinicians in this area, as well as to guide further research to inform these gaps.”
“History of cannabis as a medicine: a review” 

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.

“Cannabis-based medicines have recently been approved for the treatment of pain and spasticity in multiple sclerosis (MS).

This supports the original perceptions of people with MS, who were using illegal street cannabis for symptom control and pre-clinical testing in animal models of MS.

This activity is supported both by the biology of the disease and the biology of the cannabis plant and the endocannabinoid system.

MS results from disease that impairs neurotransmission and this is controlled by cannabinoid receptors and endogenous cannabinoid ligands. This can limit spasticity and may also influence the processes that drive the accumulation of progressive disability.”

http://www.ncbi.nlm.nih.gov/pubmed/25876933

http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/

Drugs of abuse and parkinson’s disease.

“The term “drug of abuse” is highly contextual. What constitutes a drug of abuse for one population of patients does not for another. It is therefore important to examine the needs of the patient population to properly assess the status of drugs of abuse. The focus of this article is on the bidirectional relationship between patients and drug abuse. In this paper we will introduce the dopaminergic systems of the brain in Parkinson’s and the influence of antiparkinsonian drugs upon them before discussing this synergy of condition and medication as fertile ground for drug abuse. We will then examine the relationship between drugs of abuse and Parkinson’s, both beneficial and deleterious. In summary we will draw the different strands together and speculate on the future merit of current drugs of abuse as treatments for Parkinson’s disease.”

http://www.ncbi.nlm.nih.gov/pubmed/25816790

http://www.thctotalhealthcare.com/category/parkinsons-disease/

Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in colorado.

“Complementary and alternative medicine (CAM) is frequently used by Parkinson’s disease (PD) patients. We sought to provide information on CAM use and efficacy in PD patients in the Denver metro area with particular attention to cannabis use given its recent change in legal status.

Self-reported improvement related to the use of CAM was highest for massage, art therapy, music therapy, and cannabis.

While only 4.3% of our survey responders reported use of cannabis, it ranked among the most effective CAM therapies.

Conclusions. Overall, our cross-sectional study was notable for a high rate of CAM utilization amongst PD patients and high rates of self-reported efficacy across most CAM modalities.

Cannabis was rarely used in our population but users reported high efficacy, mainly for nonmotor symptoms.”

http://www.ncbi.nlm.nih.gov/pubmed/25821504

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363882/

http://www.thctotalhealthcare.com/category/parkinsons-disease/

Cannabis in cancer care.

“Cannabis has been used in medicine for thousands of years prior to achieving its current illicit substance status.

Cannabinoids, the active components of Cannabis sativa, mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function.

Delta-9-tetrahydrocannabinol, the main bioactive cannabinoid in the plant, has been available as a prescription medication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome.

Cannabinoids may be of benefit in the treatment of cancer-related pain, possibly synergistic with opioid analgesics.

Cannabinoids have been shown to be of benefit in the treatment of HIV-related peripheral neuropathy, suggesting that they may be worthy of study in patients with other neuropathic symptoms.

Cannabinoids have a favorable drug safety profile, but their medical use is predominantly limited by their psychoactive effects and their limited bioavailability.”

http://www.ncbi.nlm.nih.gov/pubmed/25777363

http://www.thctotalhealthcare.com/category/cancer/

Is there a legitimate role for the therapeutic use of cannabinoids for symptom management in chronic kidney disease?

“Chronic pain is a common and debilitating symptom experienced in the context of numerous other physical and emotional symptoms by many patients with chronic kidney disease (CKD).

Management of pain with opioids in CKD can be problematic given the prominence of adverse effects of opioids in CKD, which may exacerbate symptoms, such as nausea, anorexia, pruritus, and insomnia, all of which impact negatively on patients’ health-related quality of life.

Novel therapeutic approaches for pain and symptom management in CKD are required.

Recent research in the area of cannabinoids (CBs) is legitimizing the use of cannabis-based medicine.

In this review, we describe the symptom burden borne by patients with CKD and review some of the key basic science and clinical literature to evaluate the potential use of CBs for the management of overall symptom burden in CKD.”

http://www.ncbi.nlm.nih.gov/pubmed/21269798

Re-branding cannabis: the next generation of chronic pain medicine?

“The field of pain medicine is at a crossroads given the epidemic of addiction and overdose deaths from prescription opioids. Cannabis and its active ingredients, cannabinoids, are a much safer therapeutic option.

Despite being slowed by legal restrictions and stigma, research continues to show that when used appropriately, cannabis is safe and effective for many forms of chronic pain and other conditions, and has no overdose levels.

Current literature indicates many chronic pain patients could be treated with cannabis alone or with lower doses of opioids.

To make progress, cannabis needs to be re-branded as a legitimate medicine and rescheduled to a more pharmacologically justifiable class of compounds.

This paper discusses the data supporting re-branding and rescheduling of cannabis.”

http://www.ncbi.nlm.nih.gov/pubmed/25537695

http://www.thctotalhealthcare.com/category/chronic-pain/

[Potential applications of marijuana and cannabinoids in medicine]

“Cannabinoids, psychoactive substances present in cannabis, have been known to mankind for hundreds of years.

Apart from 9-tetrahydrocannabinol (THC) substances found in the cannabis herb with the highest toxicological value are cannabidiol (CBD) and cannabinol (CBN).

The discovery of CB1 and CB2 receptors, located in various tissues (ranging from the brain to peripheral tissues), has defined the potential objective of these new chemical substances’ effects.

Many studies on the application of cannabinoids in the treatment of various diseases such as diabetes, neoplasms, inflammatory diseases, neurological conditions, pain and vomitting were conducted.

Drugs containing e.g. THC appear on the pharmaceutical market.

Substances affecting cannabinoid receptors may show beneficial effects…”

http://www.ncbi.nlm.nih.gov/pubmed/25518584